In lung adenocarcinoma, the most frequent histological subtype among non-small cell lung cancer (NSCLC), molecular-targeted therapy for various driver mutations such as the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) have been recently used in clinical settings to provide better clinical outcomes. This evidence concerns the gene EGFR and lung adenocarcinoma.